Clinical Trial

Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

Active, Not Recruiting Phase 1

Record status

This record was last updated June 1, 2026 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.

Summary

This study is a first-in-human (FIH), Phase 1/1b, open-label, multicenter dose escalation and dose expansion study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of JANX008 in adult subjects with advanced or metastatic carcinoma expressing EGFR.

Protocol Amendment History 23 amendments

This ClinicalTrials.gov record has been amended 23 times since 2023-03-14; most recent amendment 2026-05-28.

Status change: Recruiting → Active, Not Recruiting 2026-05-28

Status change: Not Yet Recruiting → Recruiting 2023-03-29

Trial Details

NCT Number	NCT05783622
Lead Sponsor	Janux Therapeutics
Conditions	Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Colorectal Carcinoma, Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Triple-negative Breast Cancer
Enrollment	130 participants
Start Date	2023-04-19
Primary Completion	2026-07-31 (estimated)
Study Completion	2026-10-31 (estimated)
Updated on ClinicalTrials.gov	2026-06-01